The ascension of Viagra initially drove significant progress in the medicinal sector, creating a perception of easy returns. However, placing capital in companies solely reliant on top-selling drugs like Viagra presents significant dangers. Exclusive rights expiration has resulted in generic comp

The recent surge in funding into boutique pharmaceutical companies, particularly those focusing on novel therapies and difficult drug development programs, has fueled what some are calling "High Investor Pharma." While the promise for game-changing treatments and significant returns is certain, t